These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 9140692)
21. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
22. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation. Groh WJ; Gibson KJ; Maylie JG J Cardiovasc Electrophysiol; 1997 May; 8(5):529-36. PubMed ID: 9160229 [TBL] [Abstract][Full Text] [Related]
26. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Hohnloser SH Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415 [TBL] [Abstract][Full Text] [Related]
27. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Singh BN Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824 [TBL] [Abstract][Full Text] [Related]
28. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH; Singh BN J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113 [TBL] [Abstract][Full Text] [Related]
29. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331 [TBL] [Abstract][Full Text] [Related]
30. Maastricht antiarrhythmic drug evaluator (MANTA): A computational tool for better understanding of antiarrhythmic drugs. Sutanto H; Laudy L; Clerx M; Dobrev D; Crijns HJGM; Heijman J Pharmacol Res; 2019 Oct; 148():104444. PubMed ID: 31493513 [TBL] [Abstract][Full Text] [Related]
31. Interactions between implantable cardioverter-defibrillators and class III agents. Movsowitz C; Marchlinski FE Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653 [TBL] [Abstract][Full Text] [Related]
32. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Jurkiewicz NK; Sanguinetti MC Circ Res; 1993 Jan; 72(1):75-83. PubMed ID: 8417848 [TBL] [Abstract][Full Text] [Related]
33. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. McClellan KJ; Markham A Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390 [TBL] [Abstract][Full Text] [Related]
34. Dofetilide: a new class III antiarrhythmic agent. Roukoz H; Saliba W Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453 [TBL] [Abstract][Full Text] [Related]
35. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. Eckardt L; Breithardt G; Haverkamp W J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098 [TBL] [Abstract][Full Text] [Related]
36. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Singh BN Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325 [TBL] [Abstract][Full Text] [Related]
37. [Mechanisms of action of class III anti-arrhythmia agents]. Adamantidis MM Arch Mal Coeur Vaiss; 1995 Jan; 88 Spec No 1():33-40. PubMed ID: 7786143 [TBL] [Abstract][Full Text] [Related]
38. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents. Singh BN Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731 [TBL] [Abstract][Full Text] [Related]
39. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. MacNeil DJ Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416 [TBL] [Abstract][Full Text] [Related]